Although the world has the tools – and a plan – to eliminate hepatitis C virus (HCV), it remains a threat to global public health. Untreated HCV can lead to cirrhosis and liver cancer. Each year, nearly 400,000 people die from these complications of HCV, although it has become easy to cure with 12 weeks of once-daily oral medicines, called direct-acting antivirals (DAAs). High prices have prevented access to life-saving HCV treatment across low-, middle-, and high-income countries

This community resource was developed for activists who plan to use or are using Trade-Related Aspects of Intellectual Property Rights (TRIPS) flexibilities to increase access to DAA treatment for HCV in their countries.